<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589953</url>
  </required_header>
  <id_info>
    <org_study_id>R06-04-004</org_study_id>
    <secondary_id>IND12537</secondary_id>
    <nct_id>NCT00589953</nct_id>
  </id_info>
  <brief_title>High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study</brief_title>
  <official_title>High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atlantic Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atlantic Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The highest risk for perinatal brain injury occurs among extremely premature infants who
      weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible,
      associated with neurodevelopmental disability, and without adequate treatment modalities.
      Research in recent years suggest in both animal and human studies that erythropoietin (Epo)
      may have significant neuroprotective effects. Given the historical safe medical profile of
      Epo when used for anemia of prematurity but the likely need for a greater dosage regimen for
      activation of neuroprotective pathways against neonatal brain injury, we therefore propose
      this phase II study of high-dose Epo in very low birth weight infants for the prevention
      and/or attenuation of prematurity-related cerebral hemorrhagic-ischemic injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible extremely premature infants will be enrolled in this double-blind,
      placebo-controlled randomized trial from the neonatal intensive care unit at Morristown
      Memorial Hospital (Morristown, New Jersey). Subjects will be enrolled within the first 24
      hours of life and randomly assigned to receive Epo or saline vehicle placebo.

      Standard NICU care will be provided to all subjects. Serial exams, CBC-d, reticulocyte
      counts, serum Epo levels, serial HUS, and head MRI will be collected at established time
      points during the study period. At 18 to 22 months corrected age, subjects will undergo a
      neurodevelopmental evaluation assessing for cerebral palsy, Bayley Scores of Infant
      Development-II (BSID-II) Mental Development Index (MDI), BSID-II Psychomotor Development
      Index (PDI), bilateral hearing aid use, and visual impairment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopmental evaluations at 18 to 22 months corrected age (cerebral palsy, Bayley Scores of Infant Development Mental Development Index (MDI), Psychomotor Development Index (PDI), bilateral hearing aid use, and visual impairment)</measure>
    <time_frame>18-22 months corrected age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe intraventricular hemorrhage</measure>
    <time_frame>First ten days of life</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polycythemia, neutropenia, thrombocytopenia, hypertension, sepsis, hemorrhage, seizure</measure>
    <time_frame>NICU hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Infant, Premature</condition>
  <condition>Erythropoietin</condition>
  <condition>Brain Injury</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Periventricular Leukomalacia</condition>
  <condition>Neurodevelopmental Outcomes</condition>
  <condition>Randomized Clinical Trial</condition>
  <arm_group>
    <arm_group_label>EPO###</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will be identified as a such by the study identifier &quot;EPO###&quot; where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPO ###</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be identified as a such by the study identifier &quot;EPO###&quot; where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.
The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour.</description>
    <arm_group_label>EPO ###</arm_group_label>
    <other_name>Confidential Randomization Number</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.</description>
    <arm_group_label>EPO###</arm_group_label>
    <other_name>Confidential Randomization Number</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  500 to 1250 grams at birth

          -  Less than 32 weeks gestation at birth

          -  Less than 24 hours of life at time of enrollment

        Exclusion Criteria:

          -  Congenital anomalies (chromosomal, CNS, cardiac, GI, pulmonary)

          -  Seizures within first 24 hours of life

          -  Severe neutropenia (ANC &lt; 500 cells/microL) within first 24 hours of life

          -  Polycythemia (Hct &gt; 65%) within first 24 hours of life

          -  Thrombocytopenia (platelets &lt; 50K cells/microL) within first 24 hours of life

          -  Hypertension (SBP &gt; 100mmHg) without vasopressor support within first 24 hours of life
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4.</citation>
    <PMID>3865178</PMID>
  </reference>
  <reference>
    <citation>Ascensao JL, Bilgrami S, Zanjani ED. Erythropoietin. Biology and clinical applications. Am J Pediatr Hematol Oncol. 1991 Winter;13(4):376-87. Review.</citation>
    <PMID>1785666</PMID>
  </reference>
  <reference>
    <citation>Buemi M, Aloisi C, Cavallaro E, Corica F, Floccari F, Grasso G, Lasco A, Pettinato G, Ruello A, Sturiale A, Frisina N. Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia. J Nephrol. 2002 Mar-Apr;15(2):97-103. Review.</citation>
    <PMID>12018644</PMID>
  </reference>
  <reference>
    <citation>Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003 Jan;228(1):1-14. Review.</citation>
    <PMID>12524467</PMID>
  </reference>
  <reference>
    <citation>Maier RF, Obladen M, Müller-Hansen I, Kattner E, Merz U, Arlettaz R, Groneck P, Hammer H, Kössel H, Verellen G, Stock GJ, Lacaze-Masmonteil T, Claris O, Wagner M, Matis J, Gilberg F; European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr. 2002 Jul;141(1):8-15.</citation>
    <PMID>12091844</PMID>
  </reference>
  <reference>
    <citation>Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr. 1997 Nov;131(5):661-5.</citation>
    <PMID>9403642</PMID>
  </reference>
  <reference>
    <citation>Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, Gleason CA, Bifano EM, Millard DD, Davis CB, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 1995 Jan;95(1):1-8.</citation>
    <PMID>7770284</PMID>
  </reference>
  <reference>
    <citation>Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G, Jacobs P, Malan AF. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study. Pediatrics. 1994 Jun;93(6 Pt 1):918-23.</citation>
    <PMID>8190577</PMID>
  </reference>
  <reference>
    <citation>Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S, Donovan EF, Close NC, Das A. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics. 2001 Oct;108(4):934-42.</citation>
    <PMID>11581447</PMID>
  </reference>
  <reference>
    <citation>Brown MS, Keith JF 3rd. Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial. Pediatrics. 1999 Aug;104(2 Pt 1):210-5.</citation>
    <PMID>10428996</PMID>
  </reference>
  <reference>
    <citation>Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol. 1999 Sep;19(6 Pt 1):403-6.</citation>
    <PMID>10685268</PMID>
  </reference>
  <reference>
    <citation>Maier RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, Speer CP, Fellman V, Grauel EL, Groneck P, Wagner M, Moriette G, Salle BL, Verellen G, Scigalla P. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group. J Pediatr. 1998 May;132(5):866-70.</citation>
    <PMID>9602202</PMID>
  </reference>
  <reference>
    <citation>Shalak L, Perlman JM. Hemorrhagic-ischemic cerebral injury in the preterm infant: current concepts. Clin Perinatol. 2002 Dec;29(4):745-63. Review.</citation>
    <PMID>12516744</PMID>
  </reference>
  <reference>
    <citation>Guzzetta F, Shackelford GD, Volpe S, Perlman JM, Volpe JJ. Periventricular intraparenchymal echodensities in the premature newborn: critical determinant of neurologic outcome. Pediatrics. 1986 Dec;78(6):995-1006.</citation>
    <PMID>3537951</PMID>
  </reference>
  <reference>
    <citation>Bada HS, Green RS, Pourcyrous M, Leffler CW, Korones SB, Magill HL, Arheart K, Fitch CW, Anderson GD, Somes G, et al. Indomethacin reduces the risks of severe intraventricular hemorrhage. J Pediatr. 1989 Oct;115(4):631-7.</citation>
    <PMID>2677294</PMID>
  </reference>
  <reference>
    <citation>Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001 Jun 28;344(26):1966-72.</citation>
    <PMID>11430325</PMID>
  </reference>
  <reference>
    <citation>Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004 Mar;31(1):129-42. Review.</citation>
    <PMID>15183662</PMID>
  </reference>
  <reference>
    <citation>Wen TC, Rogido M, Genetta T, Sola A. Permanent focal cerebral ischemia activates erythropoietin receptor in the neonatal rat brain. Neurosci Lett. 2004 Jan 30;355(3):165-8.</citation>
    <PMID>14732457</PMID>
  </reference>
  <reference>
    <citation>Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res. 2005 Apr;57(4):481-7. Epub 2005 Feb 17.</citation>
    <PMID>15718373</PMID>
  </reference>
  <reference>
    <citation>Sola A, Wen TC, Hamrick SE, Ferriero DM. Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr Res. 2005 May;57(5 Pt 2):110R-117R. Epub 2005 Apr 6. Review.</citation>
    <PMID>15817504</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505.</citation>
    <PMID>12435860</PMID>
  </reference>
  <reference>
    <citation>Juul SE, Harcum J, Li Y, Christensen RD. Erythropoietin is present in the cerebrospinal fluid of neonates. J Pediatr. 1997 Mar;130(3):428-30.</citation>
    <PMID>9063419</PMID>
  </reference>
  <reference>
    <citation>Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31.</citation>
    <PMID>10984541</PMID>
  </reference>
  <reference>
    <citation>Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol (1985). 1996 Jan;80(1):140-8.</citation>
    <PMID>8847295</PMID>
  </reference>
  <reference>
    <citation>Volpe JJ. Neurology of the newborn. 4th ed. Philadelphia: WB Saunders; 2001.</citation>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extreme Prematurity</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Perinatal Brain Injury</keyword>
  <keyword>Intraventricular Hemorrhage</keyword>
  <keyword>Periventricular Leukomalacia</keyword>
  <keyword>Neurodevelopmental Outcomes</keyword>
  <keyword>Randomized Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Leukomalacia, Periventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 7, 2016</submitted>
    <returned>February 1, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

